A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate Cardiovascular Outcomes During Treatment With Lixisenatide in Type 2 Diabetic Patients After an Acute Coronary Syndrome

Trial Profile

A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate Cardiovascular Outcomes During Treatment With Lixisenatide in Type 2 Diabetic Patients After an Acute Coronary Syndrome

Completed
Phase of Trial: Phase III

Latest Information Update: 22 Dec 2016

At a glance

  • Drugs Lixisenatide (Primary)
  • Indications Cardiovascular disorders; Coronary artery disease; Diabetic angiopathies; Type 2 diabetes mellitus
  • Focus Registrational; Therapeutic Use
  • Acronyms ELIXA
  • Sponsors Sanofi
  • Most Recent Events

    • 16 Nov 2016 Results assessing the association between retinopathy and neuropathy with cardiovascular events presented at the 89th Annual Scientific Sessions of the American Heart Association.
    • 27 Jul 2016 According to a Sanofi media release, lixisenatide (Adlyxin) has been approved by the US FDA for the treatment of adults with typre 2 diabetes based on results from GetGoal clinical program and ELIXA trial.
    • 25 May 2016 According to a Sanofi media release, the New Drug Application (NDA) for Lixisenatide is undergoing FDA review, with decisions anticipated in July 2016.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top